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EXPERIMENTAL STUDIES 
Hemodynamic Effects of Nitroglycerin in an Experimental Model 
Acute Aortic Regurgitation 
HARALD H. KLEPZIG, MD, KENNETH G. WARNER, MD,” SAMER Y. SIOUFFI, MD,* 
ASSAD J. SAAD, MD,* AMY HAYES, BS,* MARTIN KALTENBACH, MD, 
SHUKRI F. KHURI, MD* 
Afterload reduction is an accepted therapeutic modality for 
the treatment of congestive heart failure caused by chronic 
aortic regurgitation. However, the role of vasodilator ther- 
apy in acute aortic incompetence has not been established. 
To investigate this, left ventricular volume overload was 
produced in 18 dogs by constructing a valved conduit from 
the descending thoracic aorta to the left ventricular apex. 
The time course of aortic, pulmonary and conduit flows was 
analyzed in eight control studies and established stability of 
the experimental model. 
In the remaining 10 dogs, intravenous nitroglycerin, 
titrated to reduce mean aortic blood pressure by 40%) and 
placebo (ethanol) were each infused for 20 min periods. 
Compared with placebo, nitroglycerin significantly reduced 
aortic flow (3,945 f 324 to 3,397 + 362 mUmin, p < O.Ol), 
regurgitant flow (1,304 r?: 131 to 764 + 90 ml/min, p < 
Acute aortic regurgitation is most commonly associated with 
bacterial endocarditis and not infrequently produces severe 
left ventricular volume overload, leading to congestive heart 
failure, pulmonary edema and significant mortality (l,2). In 
this setting, employment of vasodilators has recently been 
advocated (I) to support patients before aortic valve replace- 
ment in order to establish hemodynamic stability and permit 
a therapeutic course of antibiotic therapy. The rationale for 
the use of vasodilator therapy in acute aortic incompetence 
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of 
O.OOl), septal-lateral end-diastolic diameter (47.5 + 1.8 to 
46.5 + 1.8 mm, p < O.OOl), left ventricular end-diastolic 
pressure (6.9 ?Z 0.8 to 6.0 + 0.6 mm Hg, p < 0.05), left 
ventricular stroke work (19.0 + 2.6 to 10.8 f 1.7 g-m/heat, 
p < 0.001) and systemic vascular resistance (2,253 +- 173 to 
1,433 + 117 dyne-s/cm’, p < 0.001). In contrast, pulmo- 
nary flow, left anterior descending coronary flow and 
subendocardial pH did not change during infusion of either 
nitroglycerin or placebo. 
These data indicate that by decreasing preload and 
afterload, and by preserving coronary flow and tissue pH, 
nitroglycerin effectively reduced ventricular and regurgi- 
tant volumes in the setting of acute volume overload. This 
study supports the clinical use of nitroglycerin in severe 
acute aortic incompetence. 
(J Am Co11 Cardioll989;13:927-35) 
is primarily based on investigations (3-l I) that have reported 
the effects of afterload reduction in chronic aortic regurgita- 
tion. However, aside from two clinical reports (12,13), the 
efficacy of vasodilator therapy in acute aortic incompetence 
has not been directly assessed. Hence, this study attempts to 
define the role for vasodilator therapy in this setting by 
assessing the effects of nitroglycerin in an experimental 
model of ventricular volume overload. 
Methods 
Instrumentation (Fig. 1). Eighteen mongrel dogs weigh- 
ing between 21 and 42 kg were studied. Animal care was 
conducted according to the position of the American Heart 
Association on Research Animal Use, 1984. The dogs were 
premeditated with intramuscular acepromazine (0. I mgikg 
body weight) and atropine (0.05 mgikg), and were anesthe- 
tized with intravenous sodium pentobarbital (30 mg/kg). 
Anesthesia was maintained during the course of the studies 
with supplemental doses of pentobarbital. The dogs were 
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Figure 1. A flexible conduit that contained a ball-cage valve perrnit- 
ted unidirectional flow from the aorta to the apex of the left ventricle 
(LV). Flow was measured in the proximal aorta, the main pulmo- 
nary artery (P.A.) and the conduit. Left ventricular pressure was 
recorded with a micromanometer-tipped catheter. The septal-lateral 
minor axis diameter was measured with a pair of ultrasonic crystals 
fixed to the septum and the lateral wall of the left ventricle. Left 
anterior descending (LAD) coronary flow was determined with a 
pulsed Doppler flow probe. Myocardial pH was monitored with a 
glass tip electrode inserted into the left ventricular subendocardial 
region. RA = right atrium. 
intubated and mechanically ventilated with a Harvard respi- 
rator at a tidal volume of 15 ml/kg. Supplemental oxygen (2 
to 3 liters/min) was given. Arterial blood gases were moni- 
tored (model 713, Instrumentations Laboratory, Inc.) and 
maintained in the normal range. A left lateral thoracotomy 
was performed in the fifth intercostal space, and the heart 
was suspended in a pericardial cradle. Fluid-filled catheters 
connected to Statham p23ID transducers were placed into 
the aortic arch through the right carotid artery and into the 
right atria1 appendage for measurements of aortic and right 
atria1 pressures. Left ventricular cavitary pressure and its 
first derivative (dP/dt) were recorded with a micromanom- 
eter tip catheter (PC 470 Millar Instruments) inserted 
through the anterior wall of the left ventricle. Electromag- 
netic flow probes (Biotronex Laboratories Inc.) were placed 
snugly around the ascending aorta and pulmonary artery. 
Calibration of the flow probes was performed in situ at 
completion of each study with autologous blood. A pair of 5 
MHz sonomicrometer crystals (Triton Technology Inc.) 
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were fixed to the anterior septum and the lateral wall for 
determination of left ventricular septal-lateral minor axis 
dimensions. In 12 dogs, the proximal left anterior descending 
coronary artery was dissected, and a 20 MHz pulsed Dop- 
pler flow probe (Valpey-Fisher Inc.) was placed around the 
artery before the takeoff of the first major diagonal branch. 
Measurement of myocardial pH. Myocardial tissue pH 
was measured in the subendocardial region of the left 
ventricular anterior wall with a miniature glass tip electrode 
developed in our laboratory in conjunction with Ingold 
Electrodes Inc. The characteristics and calibration of the 
electrode have been described previously (14,15). Briefly, 
the electrode was 10 mm in length and 1 mm in diameter. The 
distal portion of the electrode consisted of lead glass, which 
contained a silver-silver chloride sensing wire. The electrode 
was inserted into the myocardium and secured to the epicar- 
dium with a fine suture. A reference electrode was placed in 
a beaker containing 3 M potassium chloride (KCl) and 
connected to the subcutaneous tissue of the dog’s hind limb 
with a 2 M KC1 bridge. The electrodes were connected by 
coaxial cables to a Corning voltmeter (model 610 A) set in 
the millivolt mode. Intramyocardial temperature was mea- 
sured with a Webster thermistor. Both the millivolt and the 
temperature readings were recorded on a two channel Soltec 
recorder. The electrodes were calibrated in standard buffer 
solutions of pH 4.0 and 7.0 before and after each study. The 
95% in vitro response time of the electrode was 3 to 4 s. The 
stabilization time of the electrode was 3 to 5 min. Myocardial 
pH was calculated with use of a software program according 
to the Nernst principle (16). 
Aorta to left ventricular conduit. After instrumentation, 
200 U/kg of intravenous heparin was administered. Heparin 
was later supplemented in hourly doses of 100 units/kg. A 
flexible Dacron graft was anastomosed to the descending 
thoracic aorta in an end to side fashion (Fig. 1). The graft 
was connected by plastic tubing to a 22 mm diameter knitted 
graft that contained a ball-cage Starr-Edwards valve. The 
distal end of the graft was connected to a 28F plastic tube 
that was introduced into the left ventricular apex and se- 
cured with a tourniquet. The valve was oriented to permit 
flow from the aorta to the apex. Conduit flow was measured 
with an intraluminal electromagnetic flow meter inserted 
distal to the site of the valve. The flow meter was calibrated 
with autologous blood in situ at the end of each study. Flow 
through the conduit was controlled by adjusting a clamp 
placed around the conduit. The valved aortic-apical conduit 
was a modification of an experimental model of acute aortic 
regurgitation described by Welch et al. (17). 
Protocol. Baseline measurements were obtained before 
(baseline 1) and after (baseline 2) insertion of the conduit into 
the left ventricular apex. The conduit was then opened, and 
conduit flow was gradually increased by adjusting the clamp 
until a 50% increase in aortic pulse pressure was achieved. 
Initial pilot studies had indicated that this represented ap- 
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Figure 2. Group I comprised eight control dogs that did not receive 
pharmacologic intervention during the 60 min period after opening 
of the aorta-apical ventricular conduit. Group 2 comprised 10 dogs 
that received a 20 min infusion of placebo (ethanol) followed by a 20 
min infusion of intravenous nitroglycerin (NTG). BL #1 and #2 = 
baseline I and 2 (measurements made, respectively. before and after 
conduit insertion into the left ventricular apex). 
proximately a 30% to 40%~ regurgitant fraction (conduit 
flowiaortic flow) that could be tolerated for up to 90 min 
under stable conditions. Attempts to increase conduit flow 
such that regurgitant fraction exceeded 40% invariably re- 
sulted in the rapid onset of ventricular failure and cardiovas- 
cular collapse. 
The conduit was opened for a period of 60 min (Fig. 2). 
Conditions were allowed to stabilize during the initial 20 
min, and measurements were subsequently made at 5 min 
intervals. To investigate the stability of the model, no 
pharmacologic intervention was performed in eight dogs 
(Group 1) during the period when the conduit was opened. In 
the remaining 10 dogs (Group 2), placebo (ethanol) was 
administered by continuous intravenous infusion for 20 min 
after the stabilization period. The infusion of placebo was 
terminated at the 40 min interval after opening of the 
conduit. Nitroglycerin (Nitro-Bid, Marion Laboratories 
Inc.) was then administered by a continuous intravenous 
infusion for 20 min. The dose of nitroglycerin was titrated to 
reduce mean aortic pressure by 40%. Systolic aortic pres- 
sure was not allowed to decrease to <IO0 mm Hg. The 
effects of alcohol infusion were studied because nitroglyc- 
erin was diluted in an ethanol base, which is a known 
vasodilator substance (18). The quantity and rate of ethanol 
administration were equivalent to those delivered during an 
infusion of 100 pg/kg per min of nitroglycerin. 
Data analysis and measurements. All data are reported as 
mean values of: SEM. Measurements were averaged over 8 
to 10 cardiac cycles. Coronary flow was measured in two 
Group I dogs and in all Group 2 dogs, and is expressed as a 
percent of the baseline 2 value. Minor axis left ventricular 
end-diastolic (LVEDD) and end-systolic (LVESD) diame- 
ters were determined from the sonomicrometer signals. 
End-diastole was defined as the beginning of the upstroke of 
the left ventricular dP/dt tracing. End-systole was defined as 
the point 20 ms before the minimal dP/dt. 
Percent .rystolic shortening (%SS) of the minor axis was 
then calculated. 
bus = (LVEDD - LVESD) x 100% 
LVEDD 
Systemic t,ascular resistance (SVR) was calculated using 
mean arterial pressure (MAP), right atrial pressure (RAP) 
and pulmonary flow (Pul Flow): 
SVR = (MAP - RAP) x 80 
(dyne-s/cm”). 
Pul Flow 
Left \aentricular stroke M’ork (LVSW) was calculated with 
use of MAP. LVEDP and the stroke volume (SV): 
LVSW = (MAP - LVEDP) x SV x 0.0136 (g-m/beat). 
Statistics. Statistical significance of the time course of the 
variables was performed using Friedman’s analysis of vari- 
ance (19). Paired and unpaired data were analyzed using the 
two tailed Students t test. Correlations between various 
variables were established using linear regression. A proba- 
bility (p) value of ~0.05 was considered statistically signifi- 
cant. 
Results 
Impact of the model on ventricular mechanics. Data be- 
fore (baseline 1) and after (baseline 2) implantation of the 
aorta to left ventricle conduit (before opening) are shown in 
Table I. Insertion of the conduit created decreases in mean 
and diastolic aortic pressures, peak dP/dt and left ventricular 
stroke work. In contrast, heart rate, systolic aortic pressure, 
left ventricular end-diastolic pressure. aortic and pulmonary 
flows, systemic vascular resistance, coronary flow and myo- 
cardial pH did not change after conduit insertion. Compari- 
sons of left ventricular end-diastolic and end-systolic diam- 
eter and systolic shortening were not made until after 
introduction of the conduit. 
Data obtained at 20 min after opening oj’the conduit are 
also sho#tn in Table I. The mean regurgitant (conduit) flow 
was 1,200 + 91 mlimin. which corresponded to a mean 
regurgitant fraction (conduit flowiaortic flow) of 36 ? 3%. 
This produced significant decreases in diastolic and mean 
aortic pressures, pulmonary artery flow (effective cardiac 
output) and myocardial pH. In contrast, systolic aortic 
pressure, left ventricular end-diastolic pressure and diame- 
ter. aortic flow. systolic shortening, peak dP/dt and left 
ventricular stroke work all significantly increased. Heart 
rate, systemic vascular resistance, left ventricular end- 
systolic diameter and coronary flow did not change after 
opening of the conduit. 
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Table 1. Comparisons of Baseline Conditions and the 20 min Interval of Conduit Flow (n = 18) 
Conduit 
Baseline I Baseline 2 p Value Open 20 min p Value 
Ao pressure (mm Hg) 
Systolic 
Diastolic 
Mean 
LVEDP 
HR 
Flow (mllmin) 
Ao 
PA 
Regurg 
Regurg % 
LVEDD 
LVESD 
% ss 
SVR 
Peak dP/dT 
LVSW 
Myocardial pH 
LAD flow 
(n = 12) 
NS 
0.001 
0.001 
NS 
NS 
137 ? 5 
63 i- 4 
80 + 3 
5.1 ” 0.4 
177 ? 5 
128 + 5 
49 2 4 
70 + 4 
5.5 * 0.5 
170 2 6 
I56 f 9 0.001 
35 + 3 0.001 
69 i 4 0.05 
7.2 2 0.6 0.01 
172 2 6 NS 
2,679 + 205 
2,673 2 205 
0 
0 
- 
2,622 ? 218 
2,645 ? 218 
0 
0 
44.3 + 1.8 
40.2 2 1.7 
9.1 + 0.9 
2,443 2 212 
1.513 2 78 
13.3 * 1.5 
7.38 ? 0.05 
100 
NS 
NS 
3,532 + 239 
2,414 ir 210 
1.200 + 91 
36 + 3 
45.1 2 1.7 
39.7 + 1.7 
12.1 + 0.8 
2,558 + 226 
1,632 + 106 
17.8 + 2.0 
7.33 2 0.05 
104 ? 6.5 
0.001 
0.01 
- 
0.001 
NS 
0.001 
NS 
0.05 
0.001 
0.05 
NS 
- 
- - 
- 
2,688 + 183 
1,788 ? 72 
16.5 t 2.0 
7.33 ? 0.04 
I16 2 I4 
NS 
0.001 
0.05 
NS 
NS 
Ao = aortic; Baseline 1 and 2 = measurements made, respectively. before and after conduit insertion into the left ventricular apex; HR = heart rate 
(beatslmin); LAD flow = left anterior descending coronary flow (percent of baseline 2 measurement); LVEDD = left ventricular end-diastolic diameter (mm); 
LVEDP = left vetricular end-diastolic pressure (mm Hg); LVESD = left ventricular end-systolic diameter (mm); LVSW = left ventricular stroke work (g-mbeat); 
Peak dP/dT = maximal first derivative of left ventricular pressure (mm Hgk); PA = pulmonary artery: % SS = percent systolic shortening; Regurg % = 
regurgitant flowiaortic flow x 100: SVR = systemic vascular resistance (dyne-s/cm’). 
Effect of volume overload in Group 1. Data for Group 1 changes in the measured variables, attesting to the stability 
(no pharmacologic intervention; n = 8) at IO min intervals of the model over a 60 min period. 
after opening of the conduit are shown in Table 2. Through- Comparability of the two groups. Comparisons of hemo- 
out the period of observation, there were no significant dynamic data were made between dogs in Group 1 and 
Table 2. Hemodynamic Measurements in Group 1 During Conduit Flow (n = 8) 
20 min 30 min 40 min 50 min 60 min p Value 
Ao pressure (mm Hg) 
Systolic 
Diastolic 
Mean 
LVEDP 
HR 
Flow (mumin) 
Ao 
PA 
Regurg 
Regurg % 
LVEDD 
LVESD 
% ss 
SVR 
Peak dP/dT 
LVSW 
Myocardial pH 
151 ? 12 148 + 12 
29 i 4 28 ” 4 
56 2 5 56 ? 5 
7.5 ? 1.0 7.8 ? 1.1 
I58 + IO 156 + 10 
148 + 10 149 + 14 146 ? 9 NS 
27 t 4 29 + 5 26 + 5 NS 
56 + 6 58 + 5 56 2 4 NS 
7.7 * I.1 7.8 2 1.2 7.8 2 1.2 NS 
156 + 11 162 + 8 155 ? II NS 
3,069 + 284 3.085 t 315 
2,124 t 322 2.170 + 343 
1,064 t 123 1,034 + 119 
37 ? 5 37 2 6 
41.3 ? 3.1 41.3 ? 3.0 
36.5 ? 2.7 36.5 2 2.6 
11.6 + 0.6 11.5 + 0.6 
2.410 + 365 2,342 t 371 
1.444 ? 156 1,385 2 I55 
13.3 ? 2.5 11.8 2 1.7 
7.36 ‘- 0.06 7.34 2 0.06 
3.072 2 295 3,033 ? 237 3,035 ? 249 NS 
2,146 +- 329 2.055 + 268 2,143 + 313 NS 
1,022 + 116 I.131 2 99 990 ? 108 NS 
36 + 5 39 + 5 35 ? 5 NS 
41.4 * 3.0 41.3 ? 3.1 41.3 2 3.1 NS 
36.5 2 2.6 36.5 ? 2.7 36.5 ? 2.7 NS 
II.7 + 0.6 12.9 ? 0.9 11.7 2 0.6 NS 
2,405 ? 366 2.452 t 352 2,309 + 322 NS 
1,425 ? 151 1,508 2 136 I.331 t 98 NS 
11.6 + 4.3 12.0 + I.6 11.8 + 1.3 NS 
7.35 + 0.06 7.35 ” 0.08 7.35 ? 0.08 NS 
Abbreviations as in Table 1. 
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Group 2 (pharmacologic intervention; n = 10) at the end of 
the 20 min interval after opening of the conduit. Though the 
variances and the differences in the mean values between the 
two groups were relatively large for some of the hemody- 
namic variables (including heart rate, aortic flow, pulmonary 
flow, regurgitant flow and stroke work), these differences did 
not achieve statistical significant (p = NS). 
Effects of placebo and nitroglycerin. Illustrated strip chart 
recordings of a Group 2 dog before and during nitroglycerin 
administration are shown in Figure 3. All hemodynamic 
variables were unchanged during infusion of placebo (eth- 
anol). Compared with placebo, nitroglycerin reduced left 
ventricular end-diastolic and end-systolic diameters, regur- 
gitant and aortic flows, aortic pressures and peak dP/dt. 
Curnulutive dutrr comparing the effects of’ nitroglycerin 
und placebo in Group 2 are shown in Table 3 and Figure 4. 
The average dose of nitroglycerin required to reduce mean 
aortic pressure by 40% was 100 ? 28 pg/kg per min. In 
addition to reducing systolic, diastolic and mean aortic 
pressures, nitroglycerin significantly decreased left ventric- 
ular end-diastolic pressure, aortic flow, regurgitant flow. 
regurgitant fraction, peak dP/dt, left ventricular end-diastolic 
and end-systolic diameters, systemic vascular resistance and 
stroke work. In contrast, apparent changes in mean heart 
rate, pulmonary flow, systolic shortening, coronary flow and 
myocardial pH were insignificant during nitroglycerin infu- 
sion. 
The diminution in regurgitant J(ow during nitroglycerin 
infusion correlated with changes in left ventricular end- 
diastolic pressure (r = 0.74, p < 0.02). In addition, there was 
a significant correlation between the diminution in left ven- 
tricular end-diastolic diameter and the decrease in systemic 
Figure 3. Strip chart recordings from a representative case. Opening 
of the conduit (graft open) produced I.431 mlimin of regurgitant flow 
and increased aortic pressure and aortic flow. There were no further 
hemodynamic changes during infusion of placebo. In contrast, 
nitroglycerin (NTG) infusion resulted in reductions in left ventricu- 
lar (LV) end-diastolic and end-systolic diameter, peak dP/dT, aortic 
pressure, regurgitant flow and aortic flow. 
vascular resistance (r = 0.67, p < 0.05). The reduction in 
systemic vascular resistance during nitroglycerin infusion 
correlated with the initial value of systemic vascular resis- 
tance (r = 0.80, p < 0.01). 
Discussion 
Effects of nitroglycerin on volume overload. The acute left 
ventricular volume overload produced by the aortic- 
ventricular conduit in this model simulated the changes in 
systemic hemodynamics and ventricular loading conditions 
commonly associated with clinical aortic regurgitation. The 
Group I experiments (no pharmacologic intervention) indi- 
cated that volume overload was able to be maintained under 
stable conditions for a period of 60 min. In this setting, 
infusion of nitroglycerin resulted in a 40% reduction in 
regurgitant flow, significant decreases in left ventricular 
end-diastolic and end-systolic diameters and a 43% decrease 
in left ventricular stroke work. The absence of changes in 
systemic hemodynamics, minor axis dimensions and regur- 
gitant flow during infusion of placebo indicated that the 
potential vasodilator effects of the alcohol base of the 
nitroglycerin solution were negligible. The volume load- 
reducing effects observed during the administration of the 
Table 3. Comparison of the Effects of Nitroglycerin and Placebo in Group 2 (n = 10) 
5 min IO min 20 min 15 min 
Ao pressure 
Systolic 
Placebo 
NTG 
P 
Diastolic 
Placebo 
NTG 
P 
Mean 
Placebo 
NTG 
P 
LVtiDP 
Placebo 
NTG 
P 
159 ? 13 
120 + 9 
0.001 
41 +4 
16 + 2 
0.001 
72 k 4 
44 + 3 
0.001 
159 t 13 
127 ? IO 
0.001 
163 ? 15 
128 c I1 
0.001 
164 t 15 
130 + 10 
0.001 
41 2 4 
14 + 2 
0.001 
42 i 4 
15 ? 2 
0.001 
39 + 4 
15 t 3 
0.001 
12 2 5 
44 + 3 
0.001 
73 + 5 
44 k 3 
0.001 
71 ?4 
44 2 3 
0.001 
6.9 2 0.8 
6.2 f 0.7 
NS 
7.1 ? 0.8 
6.3 ? 0.7 
0.05 
1.2 ? 0.7 
5.9 + 0.6 
0.05 
6.9 ? 0.8 
6.0 2 0.6 
0.05 
HR 
Placebo 
NTG 
I& 
Ao 
Placebo 
NTG 
P 
184 + 7.0 
181 + 7.0 
NS 
184 ? 7.0 
183 + 7.0 
NS 
183 f 1.3 
184 + 7.3 
NS 
182 2 7.3 
183 + 7.3 
NS 
3,945 * 320 
3,205 + 311 
0.001 
2,694 k 254 
2.503 ? 270 
NS 
1,307 k 127 
801 + 108 
0.001 
3,918 + 298 
3,315 t 336 
0.01 
3,937 f 305 
3,402 + 360 
0.01 
3,945 z.k 324 
3,397 + 362 
0.01 
PA 
Placebo 
NTG 
P 
Regurg 
Placebo 
NTG 
P 
Regurg % 
Placebo 
NTG 
L&DD 
Placebo 
NTG 
L&SD 
2.678 ? 250 
2,599 ? 294 
NS 
2,690 ? 249 
2,681 ? 289 
NS 
2,710 + 270 
2,701 2 322 
NS 
1.287 t 127 
783 t 98 
0.001 
1,302 f 132 
780 k 100 
0.001 
1,304 + 131 
764 + 90 
0.001 
34 ? 2 
26 2 3 
0.001 
33 + 3 
24 2 2 
0.001 
33 _t 3 
24 k 2 
0.001 
33 ? 3 
23 + 3 
0.001 
47.5 + 1.7 
46.4 k 1.8 
0.01 
47.4 i- 1.8 
46.5 ? 1.8 
0.001 
47.5 * 1.8 
46.4 + 1.7 
0.001 
47.5 ? 1.8 
46.5 2 1.8 
0.001 
Placebo 
NTG 
AS 
Placebo 
41.4 + 2.0 
40.9 2 1.9 
0.05 
41.5 + 1.9 
40.8 + 1.9 
0.01 
41.5 + 1.9 
40.8 ? 1.9 
0.01 
41.6 ? 1.9 
40.8 ? 1.9 
0.01 
12.9 ? 1.4 
12.0 2 I.1 
NS 
12.8 + 1.3 
12.4 ? 1.2 
NS 
12.8 + 1.3 
12.1 + 1.1 
NS 
12.6 + 1.3 
12.5 t 1.1 
NS 
S:R 
Placebo 
NTG 
Peik dp/dT 
Placebo 
NTG 
L&SW 
2,275 + 190 
1.518 _+ 110 
0.001 
2.296 ? 174 
1.494 + 128 
0.001 
2.314 + 155 
1,428 k 107 
0.001 
2.253 + 173 
1,433 ? 117 
0.001 
1,765 + 139 
1.225 + 129 
0.001 
1.740 ? 134 
1.275 ? 135 
0.001 
1,765 + 126 
1.295 + 130 
0.001 
1,774 k 131 
1.320 ? 134 
0.001 
Placebo 
NTG 
MFocardial pH 
Placebo 
NTG 
L:D flow 
19.6 rt 2.6 
10.5 k 1.7 
0.001 
7.29 C 0.07 
7.29 + 0.05 
NS 
106.3 L 6.6 
99.2 2 10.0 
NS 
18.7 2 2.5 
11.0 ? 1.6 
0.001 
19.0 + 2.4 19.0 2 2.6 
10.6 + 1.7 10.8 2 1.7 
0.001 0.001 
7.28 ? 0.07 
7.28 ? 0.06 
NS 
104.6 2 8.3 
99.8 t- 9.4 
NS 
7.28 ? 0.07 
7.26 ? 0.06 
NS 
108.6 ? 9.4 
110.9 + 7.3 
NS 
7.27 ? 0.07 
7.23 -+ 0.06 
NS 
Placebo 
NTG 
P 
104.0 + 8.3 
112.9 2 13.9 
NS 
Abbreviations as in Table 1 
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Figure 4. Regurgitant (REGLJRG.) flow in Group I (n = 8. upper 
panel) was constant after opening of the conduit. In Group 2 (n = 10. 
lower panel), regurgitant flow did not change during placebo (eth- 
anol) infusion. In contrast, regurgitant flow decreased considerably 
in all dogs during nitroglycerin (NTG) infusion. Each line represents 
data from an individual experiment. 
nitroglycerin solution thus stemmed solely from the vasodi- 
later properties of nitroglycerin. 
The therapeutic, henejits qf oral and sublinguul nitrates in 
patients with chronic aortic regurgitution are produced by 
reductions in left ventricular afterload and preload (2&22). 
The prolonged volume overload state associated with 
chronic aortic regurgitation results in ventricular dilation and 
an increase in diastolic compliance (23). These adaptive 
responses permit greater tolerance of volume overload. 
Thus, the effects of therapeutic intervention in chronic aortic 
regurgitation cannot be readily extrapolated to the acutely 
decompensated volume-overloaded ventricle. The present 
investigation establishes the efficacy of vasodilator therapy 
in the uncompensated volume-overloaded ventricle. 
In the present investigation, the venodilator properties of 
nitroglycerin were manifested by reductions in left ventric- 
ular end-diastolic pressure and diastolic septal-lateral dimen- 
sions. The relatively small decrease in the minor axis dimen- 
sions may have, in part, stemmed from the structural 
constraints imparted by the stiff conduit, thus preventing 
optimal relaxation of the ventricle. Though the 2% reduction 
933 
in the septal-lateral diameter during infusion of nitroglycerin 
was relatively small, the global decrease in ventricular 
volume probably approached 6 to 8% of the initial volume, 
assuming that changes in chamber size were uniform (24,25). 
The importance of the venodilator effects was illustrated by 
the significant correlation between the change in regurgitant 
flow and the decrease in left ventricular end-diastolic pres- 
sure. 
The correlation between the diminution in left ventricular 
end-diastolic diameter and the change in systemic vascular 
resistunce indicates the importance of afterload reduction 
during nitroglycerin infusion. That the decline in systemic 
vascular resistance was most pronounced in dogs with the 
highest initial values of peripheral resistance is consistent 
with findings described in previous studies (7,20), and sug- 
gests that the afterload-reducing effects of nitroglycerin may 
be clinically most useful in patients with elevated systemic 
resistance. Despite the significant reduction in afterload, 
administration of nitroglycerin did not improve cardiac out- 
put in the setting of acute volume overload. The arterial- 
dilating effects of nitroglycerin may have been offset by its 
predominant venodilator properties, thus preventing a net 
increase in forward flow. It is conceivable that more potent 
arterial-dilating agents such as hydralazine (3,5,9.1 I) and 
sodium nitroprusside (13) would generate an increase in 
cardiac output in this setting. 
Effects of nitroglycerin on coronary flow. During nitro- 
glycerin infusion, myocardial oxygen demands were dimin- 
ished by the reductions in stroke work and ventricular 
afterload. Nitroglycerin also decreased aortic diastolic pres- 
sure and, therefore, coronary driving pressure (26). The 
simultaneous reductions in oxygen demand and coronary 
driving pressure would have been expected to reduce coro- 
nary flow during nitroglycerin infusion. However, the lack of 
change in coronary flow despite the marked reduction in 
aortic pressure suggests the presence of intact autoregula- 
tory mechanisms. This condition may have, in part, resulted 
from the direct vasodilator effect of nitroglycerin on the 
coronary resistance vessels (27,28). The absence of a change 
in myocardial pH during nitroglycerin infusion indicates 
preservation of adequate tissue perfusion in the subendocar- 
dial regions (29) and corroborates the coronary flow findings. 
The direct \wsodilator efects of nitroglycerin ure known 
to stimulate sqmprrthetic activity (30,3/). However. in our 
model, the absence of significant changes in heart rate and 
percent systolic shortening indicates that the potential ef- 
fects of increased sympathetic tone during the study proto- 
col were not appreciable. In addition, at least one report (32) 
has indicated that nitroglycerin may directly inhibit cardiac 
afferent sympathetic discharge. 
Clinical correlates. Two clinical reports (12,13) in addi- 
tion to the present study, suggest that vasodilator therapy 
may be etfective in acute aortic incompetence. An isolated 
case report (I?) showed that sublingual isosorbide dinitrate 
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improved cardiac output and reduced pulmonary capillary 
wedge pressure in a patient with congestive heart failure and 
acute aortic incompetence secondary to bacterial endocar- 
ditis. A study by Miller et al. (13) demonstrated that, in a 
small group of patients with either chronic or acute aortic 
regurgitation, afterload reduction with sodium nitroprusside 
decreased left ventricular end-diastolic pressure and regur- 
gitant flow while increasing cardiac index and ejection 
fraction. The small number of patients investigated in these 
two studies and the imprecise methods used to assess 
ventricular function diminish the impact of their findings. 
Nevertheless, they provide support for the expanded use of 
vasodilator therapy in acute aortic regurgitation. 
We thank Edward D. Folland, MD and Richard Shemin, MD for their 
comments and criticisms, and Michael Butler, Curtis Wrenn, Henry Foster 
and Steve Conray for their technical assistance. 
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